IP Library Granted Patent US 8,562,983
Granted Patent B2
US 8,562,983 · App. 12/229,428 · Granted Oct 22, 2013

System comprising elastase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,562,983
App. No.
12/229,428
Granted
Oct 22, 2013
Kind
B2
Abstract

The invention provides systems for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.

Claims (20)

1. A system for enlarging the diameter of an artery in a human subject, said artery having a lumen, the system comprising:

(a) a catheter configured for injecting a pharmaceutical composition directly into a selected segment of the wall of the artery; and

(b) a pharmaceutical composition suitable for administration to the human subject comprising an elastase,

wherein said elastase is present in a dose sufficient to enlarge the diameter of the artery and the diameter of the lumen of the artery when administered via the catheter to the wall of the artery in the human subject.

2. A system for enlarging the diameter of a vein in a human subject, said vein having a lumen, the system comprising:.

(a) a catheter configured for injecting a pharmaceutical composition directly into a selected segment of the wall of the vein; and

(b) a pharmaceutical composition suitable for administration to the human subject comprising an elastase,

wherein said elastase is present in a dose sufficient to enlarge the diameter of the vein and the diameter of the lumen of the vein when administered via the catheter to the wall of the vein in the human subject.

3. The system of claim 1 or 2 , wherein the catheter comprises a channel for delivery of said pharmaceutical composition.

4. The system of claim 3 , wherein a delivery device containing the pharmaceutical composition is connected to the catheter for delivering the pharmaceutical composition to the artery or vein via the channel.

5. The system of claim 4 , wherein the delivery device is a syringe.

6. The system of claim 1 or 2 , which is configured for delivering the pharmaceutical composition at low pressure into the wall of the artery or vein.

7. The system of claim 1 or 2 , wherein the catheter comprises at least one injector port configured for entering the wall of the artery or vein and injecting the pharmaceutical composition directly into the wall of the artery or vein.

8. The system of claim 7 , wherein said at least one injector port is mounted on the surface of one or more inflatable balloons.

9. The system of claim 1 or 2 , wherein the elastase is a pancreatic elastase.

10. The system of claim 1 or 2 , wherein the pharmaceutical composition does not comprise a collagenase.

11. The system of claim 1 or 2 , wherein the catheter comprises a plurality of injector ports configured for injecting the pharmaceutical composition directly into the wall of the artery or vein

12. The system of claim 11 , wherein said injector ports can be extended so as to enter the wall of the artery or vein.

13. . The system of claim 11 , wherein said injector ports are mounted on the surface of one or more inflatable balloons.

14. The system of claim 1 or 2 , wherein the catheter comprises a reservoir containing the elastase composition.

Assignments (10)
CHANGE OF NAME Recorded Nov 30, 2020
From: ARTARA THERAPEUTICS, INC.
To: PROTARA THERAPEUTICS, INC.
Reel/Frame 054553/0688 →
MERGER Recorded Nov 18, 2020
From: PROTEON THERAPEUTICS, INC.
To: ARTARA THERAPEUTICS, INC.
Reel/Frame 054476/0140 →
QUITCLAIM DEED Recorded Jan 19, 2011
From: FRANANO, F. NICHOLAS
To: PROTEON THERAPEUTICS, INC.
Reel/Frame 025663/0217 →
CONFIRMATORY LICENSE Recorded Dec 21, 2010
From: PROTEON THERAPEUTICS, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025528/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2010
From: NATIONAL INSTITUTES OF HEALTH
To: PROTEON THERAPEUTICS INC.
Reel/Frame 025783/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2010
From: FRANANO, F. NICHOLAS
To: PROTEON THERAPEUTICS LLC
Reel/Frame 025445/0254 →
MERGER Recorded Dec 2, 2010
From: PROTEON THERAPEUTICS LLC
To: PROTEON THERAPEUTICS, INC.
Reel/Frame 025445/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2010
From: JOHNS HOPKINS UNIVERSITY
To: FRANANO, F. NICHOLAS
Reel/Frame 025438/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2010
From: FRANANO, NICHOLAS
To: JOHNS HOPKINS UNIVERSITY
Reel/Frame 025438/0832 →
INVENTOR WAIVER REQUEST DECISION Recorded Dec 2, 2010
From: NATIONAL INSTITUTES OF HEALTH
To: FRANANO, F. NICHOLAS, MD
Reel/Frame 025438/0084 →